edaravone

Edaravone

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">edaravone</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Edaravone (Radicava)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Direct [ROS](/entities/reactive-oxygen-species) scavenger</td>
</tr>
<tr>
<td class="label">ALS Survival Benefit</td>
<td>33% mortality reduction</td>
</tr>
<tr>
<td class="label">Administration</td>
<td>IV infusion 14/28 days</td>
</tr>
<tr>
<td class="label">Side Effects</td>
<td>Injection site, rash</td>
</tr>
<tr>
<td class="label">FDA Approval</td>
<td>2017</td>
</tr>
</table>

Edaravone Mechanism of Action

Edaravone vs Standard of Care

Introduction

Edaravone

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">edaravone</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Edaravone (Radicava)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Direct [ROS](/entities/reactive-oxygen-species) scavenger</td>
</tr>
<tr>
<td class="label">ALS Survival Benefit</td>
<td>33% mortality reduction</td>
</tr>
<tr>
<td class="label">Administration</td>
<td>IV infusion 14/28 days</td>
</tr>
<tr>
<td class="label">Side Effects</td>
<td>Injection site, rash</td>
</tr>
<tr>
<td class="label">FDA Approval</td>
<td>2017</td>
</tr>
</table>

Edaravone Mechanism of Action

Edaravone vs Standard of Care

Introduction

Edaravone is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@voelker2017]

Overview

Edaravone (brand name: Radicava; also known as MCI-186; chemical name: 3-methyl-1-phenyl-2-pyrazolin-5-one) is a pyrazolone-class free radical scavenger approved for the treatment of [als](/diseases/als). The drug was first approved in Japan in 2001 for the treatment of acute ischemic stroke, and subsequently received FDA approval in May 2017 as the second drug ever approved for ALS treatment, following [riluzole](/therapeutics/riluzole) . An oral suspension formulation (Radicava ORS) was approved by the FDA in May 2022, providing a more convenient alternative to the original intravenous formulation . [@edaravone]

Edaravone's primary mechanism of action involves scavenging free radicals and reducing [oxidative-stress](/mechanisms/oxidative-stress), which is believed to contribute to motor neuron degeneration in ALS. While the exact mechanism by which edaravone slows ALS progression is not fully understood, its strong antioxidant properties are thought to protect [neurons](/entities/neurons), [astrocytes](/cell-types/astrocytes), and vascular endothelial cells from oxidative damage . Originally developed by Mitsubishi Chemical Industries (now Mitsubishi Tanabe Pharma), edaravone represents a distinct pharmacological approach to ALS treatment compared to the glutamate-modulating [riluzole](/therapeutics/riluzole), and the two drugs are frequently used together in clinical practice. [@witzel2023]

Mechanism of Action

Free Radical Scavenging

Edaravone functions as a potent free radical scavenger with the ability to neutralize both hydroxyl radicals (•OH) and peroxyl radicals (ROO•). The drug's pyrazolone ring structure enables it to donate electrons to free radicals, converting them to more stable, less reactive species. This antioxidant activity occurs through a one-electron transfer mechanism, where edaravone is oxidized to form an edaravone radical, which is subsequently metabolized to inactive products . [@banno2005]

In the context of ALS, [oxidative-stress](/mechanisms/oxidative-stress) is a well-established contributor to motor neuron degeneration. Mutations in the [sod1-protein](/proteins/sod1-protein) gene—found in approximately 2% of all ALS cases—directly impair the cell's primary antioxidant defense system, leading to accumulation of [reactive oxygen species ([oxidative-stress](/mechanisms/oxidative-stress) . Edaravone combats this oxidative burden through several complementary pathways: [@parrarivas2022]

Nrf2 Pathway Activation

Beyond direct radical scavenging, edaravone activates the Nrf2 (Nuclear factor erythroid 2-related factor 2) signaling pathway, a master regulator of cellular antioxidant responses. Activation of Nrf2 induces the expression of a battery of cytoprotective genes, including heme oxygenase-1 (HO-1), NAD(P)H quinone dehydrogenase 1 (NQO1), and glutathione S-transferases, amplifying the cell's endogenous antioxidant capacity . [@kikuchi2012]

Mitochondrial Protection

Edaravone has been shown to exert protective effects on mitochondrial function. In neurodegenerative diseases including ALS, mitochondrial dysfunction leads to increased [oxidative-stress](/mechanisms/oxidative-stress) production, impaired energy metabolism, and activation of apoptotic pathways. Edaravone preserves mitochondrial membrane potential, reduces mitochondrial [oxidative-stress](/mechanisms/oxidative-stress) generation, and prevents the release of cytochrome c, thereby inhibiting the intrinsic apoptotic cascade . [@writing2017]

Neurovascular Protection

Edaravone protects components of the neurovascular unit—including [neurons](/entities/neurons), [astrocytes](/cell-types/astrocytes), [pericytes](/cell-types/pericytes), and endothelial cells—from oxidative damage. This broad-spectrum protection is particularly relevant in ALS, where [Blood-Brain Barrier ([blood-brain-barrier](/entities/blood-brain-barrier) integrity is compromised and neurovascular dysfunction contributes to disease progression . [@miyamoto2013]

Anti-inflammatory Effects

Edaravone also demonstrates anti-inflammatory properties. It suppresses the production of pro-inflammatory cytokines and reduces activation of [microglia[/https://pmc.ncbi.nlm.nih.gov/articles/PMC5324974/[/https://pmc.ncbi.nlm.nih.gov/articles/PMC5324974/[/https://pmc.ncbi.nlm.nih.gov/articles/PMC5324974//https://pmc.ncbi.nlm.nih.gov). [@pivotal]

Pharmacology

Pharmacokinetics

Edaravone is rapidly distributed after intravenous administration, with a plasma half-life of approximately 4.5–6 hours. The drug is highly protein-bound (92%) and is primarily metabolized through glucuronide conjugation and sulfate conjugation. Edaravone and its metabolites are excreted mainly through the urine . [@brooks2024]

The oral suspension formulation (Radicava ORS) contains edaravone in a lipid-based formulation that enhances gastrointestinal absorption. The oral formulation achieves comparable bioavailability to the intravenous formulation and allows for once-daily administration at home, significantly improving convenience for patients . [@paganoni2020]

Dosing Regimen

The FDA-approved dosing regimen follows a cyclical on/off pattern: [@refineals]

• Initial treatment cycle: 60 mg administered daily for 14 days, followed by a 14-day drug-free period
• Subsequent treatment cycles: 60 mg administered daily for 10 days out of 14-day periods, followed by 14 days off treatment
• Intravenous formulation: Administered as a 60-minute infusion
• Oral formulation: Taken once daily on an empty stomach (at least 1 hour before or 2 hours after a meal)

Clinical Evidence

Pivotal Phase 3 Trial (Study 19)

The pivotal trial that led to FDA approval was a randomized, double-blind, placebo-controlled study conducted in Japan (Study MCI186-19). The trial enrolled 137 patients with ALS and demonstrated that edaravone significantly slowed the decline in the ALS Functional Rating Scale-Revised (ALSFRS-R) score compared to placebo over a 24-week treatment period . [@phase2026]

Key results:

• The change in ALSFRS-R from baseline was −5.01 ± 0.64 in the edaravone group versus −7.50 ± 0.66 in the placebo group
• The between-group difference was 2.49 points (95% CI: 0.99–3.98; p = 0.0013)
• This represents a 33% reduction in the rate of functional decline

Post-Hoc Analyses

Subsequent post-hoc analyses of the pivotal trial data using novel statistical methods (latent class analysis) have suggested that edaravone treatment results in slower ALSFRS-R decline compared to placebo across multiple predicted disease trajectories, not only in the narrowly defined pivotal trial population .

REFINE-ALS Study

The REFINE-ALS (Radicava/Edaravone Findings in Biomarkers from ALS) study is an ongoing Phase 4, prospective, multicenter, observational study designed to characterize biomarkers associated with edaravone treatment and to better understand its mechanism of action in ALS. As of mid-2023, the study had enrolled 73 participants. The study collects biofluid samples (blood, CSF) and clinical outcomes data, which are matched with the Answer ALS biorepository to identify response biomarkers .

Oral Edaravone Phase 3 Extension Study

Ongoing Phase 3 studies (MT-1186-A03) are evaluating the long-term safety and tolerability of the oral formulation over 96 weeks. These studies also examined whether a simplified once-daily dosing regimen (without the cyclical on/off pattern) might offer superior efficacy, though at 48 weeks the once-daily regimen did not demonstrate superiority over the approved on/off dosing schedule .

Safety and Adverse Effects

Edaravone is generally well tolerated. The most common adverse effects include:

• Contusion and gait disturbance: Reported more frequently with edaravone than placebo
• Headache and dermatitis: Occurring in a small percentage of patients
• Infusion-site reactions: Specific to the intravenous formulation, including bruising, swelling, and erythema
• Hypersensitivity reactions: Rare but potentially serious allergic reactions have been reported, including anaphylaxis
• Sulfite sensitivity: The intravenous formulation contains sodium bisulfite, which may cause allergic-type reactions in sulfite-sensitive individuals

Clinical Use

ALS Treatment

Edaravone is approved for the treatment of ALS in the United States, Japan, South Korea, Canada, and several other countries. In clinical practice, edaravone is often used in combination with [riluzole](/therapeutics/riluzole), as the two drugs have complementary mechanisms of action—riluzole targeting [excitotoxicity](/mechanisms/excitotoxicity) and edaravone targeting [oxidative-stress](/mechanisms/oxidative-stress) .

Acute Ischemic Stroke

In Japan and several Asian countries, edaravone has been approved for the treatment of acute ischemic stroke since 2001. [Its neuroprotective effects in stroke are attributed to the same free radical scavenging properties that underpin its ALS indication, as ischemia-reperfusion injury generates substantial oxidative stress in brain tissue](https://pmc.ncbi.nlm.nih.gov/articles/PMC6741743/).

Investigational Applications

Research is ongoing into potential applications of edaravone in other neurodegenerative conditions, including [alzheimers](/diseases/alzheimers-disease) and [parkinsons](/diseases/parkinsons-disease), where [oxidative-stress](/mechanisms/oxidative-stress) plays a significant pathogenic role. Preclinical studies suggest edaravone may protect against [amyloid-beta](/proteins/amyloid-beta) and [alpha-synuclein](/proteins/alpha-synuclein)-mediated toxicity, though clinical evidence in these indications remains limited .

See Also

• [Antisense Oligonucleotide Therapy](/therapeutics/antisense-oligonucleotide-therapy)
• [Riluzole](/therapeutics/riluzole)
• [Tofersen](/therapeutics/tofersen)

Background

The study of Edaravone has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PRMT1
• [Serine/Arginine-Rich Protein Kinase Modulation](/hypothesis/h-dca3e907) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SRPK1

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;